
USD
+$0.00
(+0.00%
)At Close (As of Dec 2, 2025)
$523.93M
Market Cap
-
P/E Ratio
-5.2
EPS
$18.00
52 Week High
$2.74
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$6.8M |
| Total Revenue | $2.6M |
| Cost Of Revenue | $6.8M |
| Costof Goods And Services Sold | $6.8M |
| Operating Income | -$121M |
| Selling General And Administrative | $29M |
| Research And Development | $90M |
| Operating Expenses | $114M |
| Investment Income Net | - |
| Net Interest Income | $2.7M |
| Interest Income | - |
| Interest Expense | $740K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.8M |
| Income Before Tax | -$118M |
| Income Tax Expense | -$4.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$114M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$118M |
| Ebitda | -$111M |
| Net Income | -$114M |
| Field | Value (USD) |
|---|---|
| Total Assets | $66M |
| Total Current Assets | $44M |
| Cash And Cash Equivalents At Carrying Value | $32M |
| Cash And Short Term Investments | $32M |
| Inventory | - |
| Current Net Receivables | $10M |
| Total Non Current Assets | $21M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $40K |
| Intangible Assets Excluding Goodwill | $40K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $4.3M |
| Short Term Investments | - |
| Other Current Assets | $1.5M |
| Other Non Current Assets | - |
| Total Liabilities | $38M |
| Total Current Liabilities | $31M |
| Current Accounts Payable | $22M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.5M |
| Total Non Current Liabilities | $7.1M |
| Capital Lease Obligations | $7M |
| Long Term Debt | - |
| Current Long Term Debt | $846K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $7.8M |
| Other Current Liabilities | $7.4M |
| Other Non Current Liabilities | $838K |
| Total Shareholder Equity | $27M |
| Treasury Stock | - |
| Retained Earnings | -$286M |
| Common Stock | $12M |
| Common Stock Shares Outstanding | $19M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$6.8M |
| Total Revenue | $2.6M |
| Cost Of Revenue | $6.8M |
| Costof Goods And Services Sold | $6.8M |
| Operating Income | -$121M |
| Selling General And Administrative | $29M |
| Research And Development | $90M |
| Operating Expenses | $114M |
| Investment Income Net | - |
| Net Interest Income | $2.7M |
| Interest Income | - |
| Interest Expense | $740K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.8M |
| Income Before Tax | -$118M |
| Income Tax Expense | -$4.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$114M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$118M |
| Ebitda | -$111M |
| Net Income | -$114M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.